Express Pharma

Waters Corporation signs agreement with BioCity

3

To launch an open access analytical laboratory at Alderley Park

Waters Corporation and BioCity, the UK-based bioscience incubator company, announced an agreement to launch an open access analytical laboratory. Located in the BioHub at Alderley Park, the laboratory will offer Waters’ state-of-the-art liquid chromatography (LC), mass spectrometry (MS) and informatics technologies, along with a suite of analytical platforms to scientists working in the pharmaceutical and life science industries.

“Engaging with scientists in the BioHub at Alderley Park provides a unique opportunity to work and partner with customers, given the geographic proximity of Waters’ Wilmslow location. We expect that this close relationship will also give us deeper insight into customer needs and challenges,” said Richard Ladd, Senior Director, Pharmaceutical Business, Waters Division.

The laboratory will be resourced with many of Waters’ latest technology offerings, including ACQUITY QDa ACQUITY H-Class, ACQUITY UPC2 and ACQUITY PDA Detector, along with the expertise required to leverage the power of these instrumentation platforms. The laboratory will also include a nuclear magnetic resonance (NMR) system provided by Manchester Science Partnerships, the owners of Alderley Park.

The Waters/ BioCity laboratory is scheduled to open in early 2016.

EP News BureauMumbai

Comments are closed.